Clinical Trials Browser

OTHER × ARX788 × 90 days × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06224673 2026-05-01

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms